L2Be Pharma SRL
The score of L2Be Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity 0 % Total assets +66 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
L2Be Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 14,987 € | ||||
| Equity | 57,221 € | ||||
| Cash | 123,358 € | ||||
| EBITDA | 21,342 € | ||||
| Total assets | 153,570 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 23 Jun 2026
- Year ended 31 Dec 2024filed on 06 Aug 2025
- Year ended 31 Dec 2023filed on 05 Jul 2024
- Year ended 31 Dec 2022filed on 29 Aug 2023
- Year ended 31 Dec 2021filed on 24 Aug 2022
L2Be Pharma's financial analysis
- Solvency37.3%sector median: 51.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of L2Be Pharma
L2Be Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0764.501.936
- VAT number
- BE0764501936
- Peppol
- Registered · 0208:0764501936 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 02 Mar 2021
- Registered office
- 7130 Binche
- Latest accounts
- 2025 · filed on 23 Jun 2026
- Activity
- Other liberal professions and professional, scientific and technical activities n.e.c. (NACE 74999)
L2Be Pharma (SRL) has been based in Binche since 2021, active in: other liberal professions and professional, scientific and technical activities n.e.c.. For 2025, it reports a net profit of 14,987 € and equity of 57,221 €; its revenue is not published. Its solvency stands at 37.3%, below the median of its sector (51.2%).
Companies similar to L2Be Pharma
Companies in the same business, of comparable size and area, outside its group.
- BR Conseils Business and other management consultancy activities Ixelles · balance sheet 187,698 €
- Luclinicare Business and other management consultancy activities Overijse · balance sheet 159,357 €
- ReWrite Research and experimental development on natural sciences and engineering Leuven · balance sheet 115,374 €
- HOP3 Business and other management consultancy activities Brussels · balance sheet 122,835 €
- Kairos Solutions Business and other management consultancy activities Seneffe · balance sheet 70,022 €
- Jaco-MED Business and other management consultancy activities Wommelgem · balance sheet 64,463 €
- FoxBioPath Research and experimental development on natural sciences and engineering Duffel · balance sheet 103,842 €
- Bio-Perspectives Research and experimental development on natural sciences and engineering Ixelles · balance sheet 206,760 €
Frequently asked questions about L2Be Pharma
What is the revenue of L2Be Pharma?
L2Be Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of L2Be Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0764501936 for L2Be Pharma, if the company is VAT-registered. Its company number (CBE) is 0764.501.936.
Where is the registered office of L2Be Pharma?
According to the CBE register, the registered office of L2Be Pharma is in 7130 Binche.
What is the equity of L2Be Pharma?
At the close of the 2025 financial year, the equity of L2Be Pharma amounts to 57,221 €, a solvency of 37.3% of total assets.
Who manages L2Be Pharma?
The register lists 1 active mandates at L2Be Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of L2Be Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →